Journal article
Economic evaluation of rivastigmine in patients with Parkinson’s disease dementia
Abstract
Background: The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated with Parkinson’s disease have been published recently. Patient-level healthcare utilisation data were also collected, and this report is the economic evaluation based on these data.Objective: To determine the cost effectiveness of rivastigmine 3–12 mg/day in patients in whom mild to moderate dementia developed at least 2 years …
Authors
Willan AR; Goeree R; Pullenayegum EM; McBurney C; Blackhouse G
Journal
PharmacoEconomics, Vol. 24, No. 1, pp. 93–106
Publisher
Springer Nature
Publication Date
1 2006
DOI
10.2165/00019053-200624010-00008
ISSN
1170-7690